These results indicated that the maintenance of lipid equilibrium holds significant importance in the impressive efficacy of the conjunction of anlotinib and PD-1/PD-L1 inhibitors in treating advanced NSCLC. This evidence concerns the gene CD274 and non-small cell lung carcinoma.